Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.
暂无分享,去创建一个
B. Spiegelman | C. Kahn | E. Rosen | M. Ristow | F. Gonzalez | L. Goodyear | M. Hirshman | I. Szanto | Lihong Chen | A. Norris | F. Gonzalez | S. Fisher | A. Jozsi
[1] Johan Auwerx,et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.
[2] E S Lander,et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. , 2000, Nature genetics.
[3] D. James,et al. A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. , 1989, Metabolism: clinical and experimental.
[4] J. Morgan. Myogenicity in vitro and in vivo of mouse muscle cells separated on discontinuous Percoll gradients , 1988, Journal of the Neurological Sciences.
[5] B. Wolffenbuttel,et al. Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. , 2000, American journal of physiology. Endocrinology and metabolism.
[6] J. Auwerx,et al. Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients , 1997, Diabetes.
[7] D. Kelly,et al. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[8] W. Saris,et al. Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. , 2000, Diabetes.
[9] J. Flatt,et al. Effect of dietary fat content on the incidence of obesity among ad libitum fed mice. , 1985, International journal of obesity.
[10] B. Spiegelman,et al. PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. , 2001, The Journal of biological chemistry.
[11] S. Mudaliar,et al. Peroxisome Proliferator-Activated Receptor (PPAR) γ and Retinoid X Receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle , 2001, Diabetologia.
[12] C. Glass,et al. Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux , 2002, Molecular and Cellular Biology.
[13] G. Cooney,et al. Peroxisome Proliferator—Activated Receptor (PPAR)-α Activation Lowers Muscle Lipids and Improves Insulin Sensitivity in High Fat—Fed Rats Comparison With PPAR-γ Activation , 2001 .
[14] K. Umesono,et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.
[15] K. Heidenreich,et al. In vitro studies on the action of CS-045, a new antidiabetic agent. , 1990, Metabolism: clinical and experimental.
[16] B. Spiegelman,et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. , 2002, Genes & development.
[17] J. Holder,et al. Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. , 2002, Diabetes.
[18] R. Evans,et al. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. , 2000, The Journal of clinical investigation.
[19] J. Kolls,et al. Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. , 2000, Diabetes.
[20] K. Chien,et al. PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .
[21] E. Ravussin,et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. , 1993, The New England journal of medicine.
[22] G. Cooney,et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. , 2001, Diabetes.
[23] R. N. Bergman,et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study , 1992, The Lancet.
[24] W. Wilfinger,et al. Dissociation and enrichment of rat atrial myocytes containing atrial natriuretic factor (ANF). , 1986, Hormone research.
[25] S. Mudaliar,et al. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. , 2001, Diabetologia.
[26] R. Evans,et al. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency , 2000 .
[27] R. Larkins,et al. Evolution of Insulin Resistance in New Zealand Obese Mice , 1991, Diabetes.
[28] K. Moulder,et al. Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.
[29] J. Berger,et al. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. , 1998, Endocrinology.
[30] M. Lazar,et al. The hormone resistin links obesity to diabetes , 2001, Nature.
[31] K. Dudzinski,et al. A technique for the combination of clearing, staining, and injecting small mammals. , 1990, Stain technology.
[32] B. Brewer,et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. , 2003, The Journal of clinical investigation.
[33] B. Spiegelman. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.
[34] T. Willson,et al. Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor γ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues. , 2001, Endocrinology.
[35] Margaret S. Wu,et al. Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer ( PPAR g Agonist ) Action , 1998 .
[36] M. Vranic,et al. A moderate decline in specific activity does not lead to an underestimation of hepatic glucose production during a glucose clamp. , 1996, Metabolism: clinical and experimental.
[37] L. Mandarino,et al. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. , 2000, Diabetes.
[38] S. O’Rahilly,et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.
[39] J. Auwerx,et al. Induction of the Fatty Acid Transport Protein 1 and Acyl-CoA Synthase Genes by Dimer-selective Rexinoids Suggests That the Peroxisome Proliferator-activated Receptor-Retinoid X Receptor Heterodimer Is Their Molecular Target* , 2000, The Journal of Biological Chemistry.
[40] Y. Terauchi,et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. , 2001, The Journal of biological chemistry.
[41] C. Kahn,et al. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. , 2000, The Journal of clinical investigation.
[42] Jens C. Brüning,et al. Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression , 1999, Nature Genetics.
[43] M. Jimenez-Linan,et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.
[44] R. Evans,et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.
[45] K. Petersen,et al. Mechanism of troglitazone action in type 2 diabetes. , 2000, Diabetes.
[46] C. Kahn,et al. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. , 2001, The Journal of clinical investigation.
[47] J. Auwerx,et al. Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat , 1997, Diabetes.
[48] J. Olefsky,et al. Skeletal muscle peroxisome proliferator- activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus. , 1998, The Journal of clinical investigation.
[49] L. Hennighausen,et al. Loss of the Peroxisome Proliferation-activated Receptor gamma (PPARγ) Does Not Affect Mammary Development and Propensity for Tumor Formation but Leads to Reduced Fertility* , 2002, The Journal of Biological Chemistry.
[50] Tatsuya Hayashi,et al. Evidence for 5′AMP-Activated Protein Kinase Mediation of the Effect of Muscle Contraction on Glucose Transport , 1998, Diabetes.
[51] J. Peters,et al. Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)* , 1998, The Journal of Biological Chemistry.
[52] M. Vranic,et al. Determinants of glucose turnover in the pathophysiology of diabetes: an in vivo analysis in diabetic dogs. , 1996, Diabetes & metabolism.
[53] C. Kahn,et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance , 2000, Nature Medicine.
[54] J. Filmus,et al. Transforming Growth Factor-α Prevents Detachment-induced Inhibition of c-Src Kinase Activity, Bcl-XLDown-regulation, and Apoptosis of Intestinal Epithelial Cells* , 2001, The Journal of Biological Chemistry.
[55] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[56] W. Kraus,et al. Fatty Acid Homeostasis and Induction of Lipid Regulatory Genes in Skeletal Muscles of Peroxisome Proliferator-activated Receptor (PPAR) α Knock-out Mice , 2002, The Journal of Biological Chemistry.
[57] M. Lazar,et al. Resistin and obesity-associated insulin resistance , 2002, Trends in Endocrinology & Metabolism.
[58] J. Peters,et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). , 1998, The Journal of biological chemistry.
[59] A. Pfeiffer,et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. , 1998, The New England journal of medicine.
[60] J. Lehmann,et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.
[61] B. Spiegelman,et al. PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.
[62] M. Matsuda,et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.
[63] L. Chao,et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. , 2000, The Journal of clinical investigation.
[64] T. Ishihara,et al. Actions of novel antidiabetic thiazolidinedione, T‐174, in animal models of non‐insulin‐dependent diabetes mellitus (NIDDM) and in cultured muscle cells , 1998, British journal of pharmacology.
[65] R. DeFronzo,et al. The Effect of Insulin on the Disposal of Intravenous Glucose: Results from Indirect Calorimetry and Hepatic and Femoral Venous Catheterization , 1981, Diabetes.
[66] D. Archer,et al. Monoamine oxidase activities in dissociated cell fractions from rat skeletal muscle , 1986, The Journal of pharmacy and pharmacology.
[67] P. Scherer,et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.
[68] C. Kahn,et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. , 1998, Molecular cell.
[69] P. Chambon,et al. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[70] G. Cooney,et al. Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle. , 2000, The Journal of clinical endocrinology and metabolism.
[71] Y. Terauchi,et al. The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance* , 2001, The Journal of Biological Chemistry.
[72] J. McGarry,et al. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. , 2001, Diabetes.
[73] C. Burant,et al. Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.
[74] G R Stark,et al. Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl-paper and rapid hybridization by using dextran sulfate. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[75] M. Loeken,et al. Reduced expression of Pax-3 is associated with overexpression of cdc46 in the mouse embryo , 1998, Development Genes and Evolution.
[76] A. Hevener,et al. Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats. , 2001, Diabetes.